Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma.

Rosenbaum E, Hosler G, Zahurak M, Cohen Y, Sidransky D, Westra WH.

Mod Pathol. 2005 Jul;18(7):898-902.

2.

BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.

Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH.

Mod Pathol. 2004 Nov;17(11):1359-63.

3.

No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.

Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT.

Clin Endocrinol (Oxf). 2005 Oct;63(4):461-6.

PMID:
16181240
4.

Oncogenic alterations in papillary thyroid cancers of young patients.

Sassolas G, Hafdi-Nejjari Z, Ferraro A, Decaussin-Petrucci M, Rousset B, Borson-Chazot F, Borbone E, Berger N, Fusco A.

Thyroid. 2012 Jan;22(1):17-26. doi: 10.1089/thy.2011.0215. Epub 2011 Dec 7.

PMID:
22150560
5.

Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.

Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE.

Am J Surg Pathol. 2006 Feb;30(2):216-22.

PMID:
16434896
6.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.

PMID:
18070147
7.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

8.

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).

Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E.

Clin Endocrinol (Oxf). 2006 Jan;64(1):105-9.

PMID:
16402937
9.

Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct.

Finkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chhieng DC, Carling T, Roman SA, Sosa JA, Udelsman R, Theoharis CG, Prasad ML.

Histopathology. 2012 Jun;60(7):1052-9. doi: 10.1111/j.1365-2559.2011.04149.x. Epub 2012 Feb 15.

PMID:
22335197
10.

Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.

Stanojevic B, Dzodic R, Saenko V, Milovanovic Z, Pupic G, Zivkovic O, Markovic I, Djurisic I, Buta M, Dimitrijevic B, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S.

Endocr J. 2011;58(5):381-93. Epub 2011 Apr 15.

11.

Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements.

Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW.

Mod Pathol. 2007 Jul;20(7):779-87. Epub 2007 Apr 27.

12.

Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.

Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE.

Cancer Lett. 2004 Jun 8;209(1):1-6.

PMID:
15145515
13.

Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.

Brzeziańska E, Pastuszak-Lewandoska D, Wojciechowska K, Migdalska-Sek M, Cyniak-Magierska A, Nawrot E, Lewiński A.

Neuro Endocrinol Lett. 2007 Aug;28(4):351-9.

PMID:
17693984
14.

BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.

Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML.

Mod Pathol. 2013 Jan;26(1):62-70. doi: 10.1038/modpathol.2012.152. Epub 2012 Aug 24.

15.

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.

Cancer Res. 2003 Aug 1;63(15):4561-7.

16.

The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.

Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K.

Mol Carcinog. 2007 Mar;46(3):242-8.

PMID:
17186541
17.

Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R.

Endocr Relat Cancer. 2006 Jun;13(2):455-64.

18.

BRAF mutations in an Italian cohort of thyroid cancers.

Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P.

Clin Endocrinol (Oxf). 2004 Aug;61(2):239-43.

PMID:
15272920
19.

BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.

Jakubowski M, Hunt JL.

Am J Surg Pathol. 2009 Nov;33(11):1590-3. doi: 10.1097/PAS.0b013e3181b7c7ae.

PMID:
19738460
20.

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.

Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V.

Mod Pathol. 2010 Aug;23(8):1052-60. doi: 10.1038/modpathol.2010.86. Epub 2010 May 14.

Supplemental Content

Support Center